Spexis AG
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase … Read more
Market Cap & Net Worth: Spexis AG (SPEX)
Spexis AG (SW:SPEX) has a market capitalization of $317.64 Billion (CHF290.86 Billion) as of March 18, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #31883 globally and #122 in its home market, demonstrating a -5.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Spexis AG's stock price CHF4298.50 by its total outstanding shares 67664496 (67.66 Million).
Spexis AG Market Cap History: 2018 to 2025
Spexis AG's market capitalization history from 2018 to 2025. Data shows growth from $1.32 Billion to $317.64 Billion (98.47% CAGR).
Spexis AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Spexis AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
42.18x
Spexis AG's market cap is 42.18 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $583.78 Million | $10.04K | -$64.67 Million | 58145.37x | N/A |
| 2020 | $602.25 Million | $14.28 Million | -$44.95 Million | 42.18x | N/A |
Competitor Companies of SPEX by Market Capitalization
Companies near Spexis AG in the global market cap rankings as of March 18, 2026.
Key companies related to Spexis AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Spexis AG Historical Marketcap From 2018 to 2025
Between 2018 and today, Spexis AG's market cap moved from $1.32 Billion to $ 317.64 Billion, with a yearly change of 98.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CHF317.64 Billion | +6612976.92% |
| 2024 | CHF4.80 Million | +58.54% |
| 2023 | CHF3.03 Million | -90.00% |
| 2022 | CHF30.30 Million | -75.60% |
| 2021 | CHF124.15 Million | -79.39% |
| 2020 | CHF602.25 Million | +3.16% |
| 2019 | CHF583.78 Million | -55.72% |
| 2018 | CHF1.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Spexis AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $317.64 Billion USD |
| MoneyControl | $317.64 Billion USD |
| MarketWatch | $317.64 Billion USD |
| marketcap.company | $317.64 Billion USD |
| Reuters | $317.64 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.